Boston Scientific Corporation Stock Price and Value Analysis

Boston Scientific Corporation (NYSE:BSX) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Boston Scientific Corporation to reach your target.

Target type

BSX Free Cash Flow Trend

Free Cash Flow trendline for BSX
Free Cash Flow trendline for Boston Scientific Corporation
CSV

Based on historical returns, we believe that Boston Scientific Corporation can grow its free cash at a rate of about 3%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is very stable.
  • This company has wild ups and downs.
  • This company is making money at a modest rate.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the BSX Numbers

BSX Price
(Boston Scientific Corporation stock price per share)
$41.98
[?] BSX Fair Price
(based on intrinsic value)
$28.16
[?] BSX Safety Price (based on a variable margin of safety) $22.53
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 12% lower than other Healthcare stocks
[?] PE Ratio versus Industry 2275% higher than other Medical Devices stocks
[?] Cash Yield 1.90%
[?] Free Cash Flow Jitter 55%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 35,113,858 shares shorted. With 1,445,182,781 shares available for purchase and an average trading volume over the past 10 trading days of 13,974,770, it would take at least 2.5 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 885725 571
2008 885725 854
2009 885725 489
2010 885725 -2.2
2011 885725 685
2012 885725 985
2013 885725 838
2014 885725 1,008
2015 885725 435
2016 885725 911
2017 885725 1,137
2018 885725 6.6
2019 885725 1,492
2020 885725 1,138
2021 885725 1,465
2022 885725 1,067
2023 885725 1,965
2024 885725 2,831
2025 885725 3,830

Download the yearly data as CSV.

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 8 fiscal years from 2011 to 2023 with dividend or share repurchase facts, estimated free cash flow totaled $9,151 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 4 of those years with dividend payment facts, dividends paid totaled $166 million, 2.9% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 4 of those 4 years.

In 5 of the 8 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $2,252 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2023, dividends paid were $28 million, 1.4% of estimated free cash flow of $1,965 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2011 685 n/a 492 492 71.8%
2012 985 n/a 600 600 60.9%
2013 838 n/a 500 500 59.7%
2014 1,008 n/a 125 125 12.4%
2020 1,138 28 535 563 49.5%
2021 1,465 55 n/a 55 3.8%
2022 1,067 55 n/a 55 5.2%
2023 1,965 28 n/a 28 1.4%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $8,357 million in 2007 and $20,074 million in 2025, a compound annual growth rate of 5.0% over 18 years.

Revenue rose 19.9% from 2024 to 2025.

Our estimated free cash flow was $3,830 million in 2025, 19.1% of revenue. In 2007 the estimated margin was 6.8%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 8,357 571 6.8%
2008 8,050 854 10.6%
2009 8,188 489 6.0%
2010 7,806 -2.2 -0.0%
2011 7,622 685 9.0%
2012 6,958 985 14.2%
2013 7,072 838 11.9%
2014 7,462 1,008 13.5%
2015 8,068 435 5.4%
2016 9,076 911 10.0%
2017 9,048 1,137 12.6%
2018 9,823 6.6 0.1%
2019 10,735 1,492 13.9%
2020 9,913 1,138 11.5%
2021 11,888 1,465 12.3%
2022 12,682 1,067 8.4%
2023 14,240 1,965 13.8%
2024 16,747 2,831 16.9%
2025 20,074 3,830 19.1%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $1,965 million against total liabilities of $19,201 million, or 10.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 44.0% of total assets in 2025, compared with 51.5% in 2008, a decrease of 7.5 percentage points.

Stockholders equity was $24,472 million in 2025, compared with $13,174 million in 2008, a rise of 85.8%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 10.6% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 27,139 1,641 13,965 13,174
2009 25,177 864 12,876 12,301
2010 22,128 213 10,832 11,296
2011 21,290 267 9,937 11,353
2012 17,154 207 10,284 6,870
2013 16,571 217 10,032 6,539
2014 17,024 587 10,567 6,457
2015 18,133 319 11,813 6,320
2016 18,096 196 11,363 6,733
2017 19,042 188 12,030 7,012
2018 20,999 146 12,273 8,726
2019 30,565 217 16,688 13,877
2020 30,777 1,734 15,451 15,326
2021 32,229 1,925 15,607 16,622
2022 32,469 928 14,896 17,573
2023 35,136 865 15,606 19,530
2024 39,395 414 17,392 22,003
2025 43,673 1,965 19,201 24,472

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $41.98, our model's value equals that price if free cash flow grows an average of 14.0 percent a year over the 10 projection years. Our model assumes 3.3 percent a year for this stock, so the price implies growth of 14.0 percent, which is above the 3.3 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $1,158 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $33.58 8.5%
Current price $41.98 14.0%
20 percent above the current price $50.38 17.9%
Our model (stored fair price) $28.16 3.3%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

At $41.98, the price is above our fair value estimate of $28.16 for Boston Scientific Corporation.

Only 18 of the 19 fiscal years under Boston Scientific Corporation's current filer show positive free cash flow.

Comparing the first and last three years of data, average free cash flow rose sharply: $638 million at the start and $2,875 million most recently.

Year-to-year variability in free cash flow is volatile, measured at 55%.

Our value investing guide explains how to test these numbers against the filings themselves.

No dividend yield is recorded for Boston Scientific Corporation in our data.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 12% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 2275% above the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to Boston Scientific Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Boston Scientific Corporation (BSX) 60,849 17.7 - 1.9% 49% above
ResMed (RMD) 33,143 21.5 1.0% 1.2% 81% above
3M Company (MMM) 91,973 26.6 1.7% 7.0% 42% below
DexCom (DXCM) 29,582 31.2 - 0.1% 864% above
West Pharmaceutical Services (WST) 27,189 43.8 0.2% 0.6% 320% above
Baxter International (BAX) 13,135 - 0.2% 11.4% 61% below
Penumbra (PEN) 12,578 80.4 - - 781% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 885725.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 1 of the 19 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: BSX annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in BSX

Does Boston Scientific Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: BSX

This example shows how we apply the Trendshare checklist to BSX: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 41.98
    • Market cap: $61B
    • EPS: 2.37
  2. Step 2 — Valuation checks

    • P/E: 17.713
    • FCF yield: 1.9%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.